1. OP0136 Baseline Characteristics of Patients with Active Systemic JIA Successfully Discontinuing Corticosteroid while Receiving Canakinumab: Secondary Analysis from a Pivotal Phase 3 Trial. (23rd January 2014) Authors: Ruperto, N.; Brunner, H.; Constantin, T.; Wulffraat, N.; Horneff, G.; Anton, J.; Berner, R.; Corona, F.; Cuttica, R.; Desjonqueres, M.; Fischbach, M.; Alessio, M.; Chieng, A.; Emminger, W.; Haddad, E.; Lheritier, K.; Abrams, K.; Hruska, J.; Kim, D.; Martini, A. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗